2022/07/04

Novation and UofMontreal present at Target ALS annual meeting in Boston, MA


2022/01/19

Dr. Roland Bürli joins Novation's Scientific Advisory Board


2021/04/30

Novation and UofMontreal/CRCHUM consortia present at Target ALS annual meeting


2020/07/13

Target ALS award for Novation and UofMontreal/CRCHUM collaboration


2018/12/04

Novation presents at first RNA-targeted drug discovery summit


2016/01/19

Dr. Andrew MacKenzie joins Novation's Scientific Advisory Board


2016/01/01

Novation files US patent on oral cytokine inhibitor


2013/05/07

Novation establishes research collaboration with Boehringer Ingelheiim


2013/04/22

Novation receives Notice of Issuance by Canadian Patent office for QUEST Technology


2012/10/22

Novation receives Notice of Allowance by Canadian Patent office for QUEST Technology


2010/07/20

Novation receives contribution from NRC IRAP


2009/06/11

Novation and Cancer Therapeutics begin collaboration on discovery and development of new cancer therapies


2009/06/02

Notice of Allowance from US Patent Office for Quest Drug Discovery Technology


2009/01/07

Quest drug discovery assay available for identifying inhibitors of IL-6


2008/11/17

Quest oncology drug discovery assays for intractable cancer targets


2008/10/30

Drug discovery assay for identifying new therapeutics for neurological diseases


2008/09/11

Dr. Inder Verma joins Novation Scientific Advisory Board


2007/09/04

Novation receives Notice of Intent to Grant from European Patent Office


2006/02/05

Novation appoints two new members to Board of Directors


2005/11/23

Novation Pharmaceuticals Commences mRNA Small Molecule Drug Discovery Project with Novartis




A NEW PARADIGM IN SMALL-MOLECULE DRUG DISCOVERY



Novation Pharmaceuticals is using a new approach, modulation of intracellular messenger RNA (mRNA), to identify new small-molecule therapies to treat serious diseases. Novation's technology, called QUEST, is a breakthrough in identifying new, orally active small molecule drugs for significant therapeutic targets.

Novation is seeking to build a product focused business based on modulation of mRNA. Priority is to discover its own products using QUEST, whilst generating early revenues through strategic partnerships with pharmaceutical companies.

Novation's QUEST technology -- taking drug discovery to a new level